Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis

Clinical Psychology: Science and Practice

Volumn 12, Issue 1, 2005, Pages 72-86

  Otto, Michael W ^a,b   Smits, Jasper A J ^a   Reese, Hannah E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Anxiety disorders; Bipolar disorder; Cognitive behavior therapy; Combination treatment; Depression; Psychopharmacology

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CLOMIPRAMINE; CYCLOSERINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; BEHAVIOR THERAPY; BIPOLAR DISORDER; CHRONIC DISEASE; CHRONICITY; CLINICAL TRIAL; COGNITIVE THERAPY; COST BENEFIT ANALYSIS; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; FAMILY THERAPY; FOLLOW UP; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; META ANALYSIS; MOOD DISORDER; NONHUMAN; PATIENT COMPLIANCE; PRIMARY PREVENTION; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RELAPSE; REVIEW; SYSTEMATIC REVIEW;

EID: 14644431769     PISSN: 09695893     EISSN: None     Source Type: Journal    
DOI: 10.1093/clipsy/bpi009     Document Type: Review

References (93)

1. Antonuccio, D. O., Thomas, M., & Danton, W. G. (1997). A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression. Behavior Therapy, 28, 187-210.
2. Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000). Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Journal of the American Medical Association, 283, 2529-2536.
3. Beck, A. T., Hollon, S. D., Young, J. E., Bedrosian, R. C., & Budenz, D. (1985). Treatment of depression with cognitive therapy and amitriptyline. Archives of General Psychiatry, 42, 142-148.
4. Blackburn, I. M., Bishop, S., Glen, A. I., Whalley, L. J., & Christie, J. E. (1981). The efficacy of cognitive therapy in depression: A treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. British Journal of Psychiatry, 139, 181-189.
5. Blomhoff, S., Haug, T. T., Hellström, K., Holme, I., Humble, M., Madsbu, H. P., et al. (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. British Journal of Psychiatry, 179, 23-30.
6. Bouton, M. E. (2002). Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biological Psychiatry, 52, 976-986.
7. Bouton, M. E., Kenney, F. A., & Rosengard, C. (1990). State dependent fear extinction with two benzodiazepine tranquilizers. Behavioral Neuroscience, 104, 44-55.
8. Bowers, W. A. (1990). Treatment of depressed in-patients: Cognitive therapy plus medication, relaxation plus medication, and medication alone. British Journal of Psychiatry, 157, 73-78.
9. Browne, G., Steinera, M., Roberts, J., Gafnia, A., Byrnea, C., Dunnf, E., et al. (2002). Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. Journal of Affective Disorders, 68, 317-330.
10. Christensen, H., Hadzi-Pavlovic, D., Andrews, G., & Mattick, R. (1987). Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: A quantitative review. Journal of Consulting and Clinical Psychology, 55, 701-711.
11. Cochran, S. (1984). Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. Journal of Consulting and Clinical Psychology, 52, 873-878.
12. Cohen, J. (1977). Statistical power analysis for the behavioral sciences (Rev. ed.). San Diego, CA: Academic Press.
13. Colom, F., Vieta, E., Martinez-Aran, A., Reinares, M., Goikolea, J. M., Benabarre, A., et al. (2003). A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of General Psychiatry, 60, 402-407.
14. Cottraux, J., Mollard, E., Bouvard, M., Marks, I., Sluys, M., Nury, A. M., et al. (1990). A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology, 5, 17-30.
15. Cowley, D. S., Ha, E. H., & Roy-Byrne, P. P. (1997). Determinants of pharmacologic treatment failure in panic disorder. Journal of Clinical Psychiatry, 58(12), 555-561.
16. Craighead, W. E., & Miklowitz, D. J. (2000). Psychosocial interventions for bipolar disorder. Journal of Clinical Psychiatry, 61 Suppl. 13), 58-64.
17. Davis, M., Falls, W. A., & Gewirtz, J. (2000). Neural systems involved in fear inhibition: Extinction and conditioned inhibition. In M. Myslobodsky & I. Weiner (Eds.), Contemporary issues in modeling psychopathology (pp.113-142). Boston: Kluwer.
18. Davis, M., & Myers, K. M. (2002). The role of glutamate and gamma-aminobutyric acid in fear extinction: Clinical implications for exposure therapy. Biological Psychiatry, 52, 998 1007.
19. Dobson, K. S. (1989). A meta-analysis of the efficacy of cognitive therapy for depression. Journal of Consulting and Clinical Psychology, 57, 414-419.
20. Evans, M., Hollon, S., DeRubeis, R., Piasecki, J., Grove, W., Garvey, M., et al. (1992). Differential relapse following cognitive therapy and pharmacotherapy for depression. Archives of General Psychiatry, 49, 802-808.
21. Fava, G. A. (2003). Can long-term treatment with antidepressant drugs worsen the course of depression? Journal of Clinical Psychiatry, 64, 123-133.
22. Fava, G. A., Grandi, S., Zielezny, M., Rafanelli, C., & Canastrari, R. (1996). Four year outcome for cognitive behavioral treatment of residual symptoms in major depression. American Journal of Psychiatry, 153, 945-947.
23. Fava, G. A., Rafanelli, C., Grandi, S., Canastrari, R., & Morphy, M. A. (1998). Six year outcome for cognitive behavioral treatment of residual symptoms in major depression. American Journal of Psychiatry, 155, 1443-1445.
24. Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., & Belluardo, P. (1998). Prevention of recurrent depression with cognitive behavioral therapy. Archives of General Psychiatry, 55, 816-820.
25. Fava, G. A., Savron, G., Grandi, S., & Rafanelli, C. (1997a). Cognitive behavioral treatment of drug resistant major depression disorder. Journal of Clinical Psychiatry, 58, 278-282.
26. Fava, G. A., Savron, G., Zielezny, M., Grandi, S., Rafanelli, C., & Conti, S. (1997b). Overcoming resistance to exposure in panic disorder with agoraphobia. Acta Psychiatrica Scandinavica, 95, 306 312.
27. Foa, E. B., Franklin, M. E., & Moser, J. (2002). Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biological Psychiatry, 10, 987-997.
28. Frank, E., Kupfer, D. J., Wagner, E. F., McEachran, A. B., & Cornes, C. (1991). Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: Continuing factors. Archives of General Psychiatry, 48, 1053-1059.
29. Franklin, M. E., Abramowitz, J. S., Bux, D. A., Zoellner, L. A., & Feeny, N. C. (2002). Cognitive-behavioral therapy with and without medication in the treatment of obsessive-compulsive disorder. Professional Psychology: Research and Practice, 33, 162-168.
30. Friedman, M. A., Detweiler-Bedell, J. B., Leventhal, H. E., Horne, R., Keitner, G. I, & Miller, I. W. (2004). Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. Clinical Psychology: Science and Practice, 11, 47-68.
31. Fyer, A. J., Liebowitz, M. R., Gorman, J. M., Campeas, R., Levin, A., Davies, S. O., et al. (1987). Discontinuation of alprazolam treatment in panic patients. American Journal of Psychiatry, 144, 303-308.
32. Gitlin, M. J., Swendsen, J., Heller, T. L., & Hammen, C. (1995). Relapse and impairment in bipolar disorder. American Journal of Psychiatry, 152, 1635-1640.
33. Goldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., et al. (2004). Modulation of cortical-limbic pathways in major depression: Treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry, 61, 34-41.
34. Gould, R. A., Buckminster, S., Pollack, M. H., Otto, M. W., & Yap, L. (1997). Cognitive-behavioral and pharmacological treatment for social phobia: A meta-analysis. Clinical Psychology: Science and Practice, 4, 291-306.
35. Gould, R. A., Otto, M. W., & Pollack, M. H. (1995). A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review, 15, 819-844.
36. Gould, R. A., Otto, M. W., Pollack, M. P., & Yap, L. (1997). Cognitive-behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis. Behavior Therapy, 28, 285-305.
37. Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., & Fisher, S. (1992). A meta-analysis of antidepressant outcome under "blinder" conditions. Journal of Consulting and Clinical Psychology, 60, 664-669.
38. Haug, T. T., Blomhoff, S., Hellström, K., Holme, I, Humble, M., Madsbu, H. P., et al. (2003). Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. British Journal of Psychiatry, 182, 312-318.
39. Hegel, M. T., Ravaris, C. L., & Ahles, T. A. (1994). Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder. Behavior Therapy, 25, 183-195.
40. Heimberg, R. G., Salzman, D. G., Holt, C. S., & Blendell, K. A. (1993). Cognitive-behavioral group treatment for social phobia: Effectiveness at five-year follow-up. Cognitive Therapy and Research, 17, 325-339.
41. Hembree, E. A., Riggs, D. S., Kozak, M. J., Franklin, M. E., & Foa, E. B. (2003). Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectrums, 8, 363-371.
42. Hofmann, S. G., Barlow, D. H, Papp, L. A., Detweiler, M. F., Ray, S. E., Shear, M. K., et al. (1998). Pretreatment attrition in a comparative treatment outcome study on panic disorder. American Journal of Psychiatry, 155, 43-47.
43. Hohagen, F., Winkelmann, G., Räsche-Rauschle, H, Hand, I., König, A., Münchau, N., et al. (1998). Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: Results of a multicentre study. British Journal of Psychiatry, 35(Suppl.), 71 78.
44. Hollon, S. D., DeRubeis, R. J., Evans, M. D., Wiemer, M. J., Garvey, M. J., Grove, W. M., et al. (1992). Cognitive therapy and pharmacotherapy for depression: Singly and in combination. Archives of General Psychiatry, 49, 774-781.
45. Hooper, M., & Amsterdam, J. D. (1998, June). Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants. Poster session presented at the annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL.
46. Johnson, R. E., & McFarland, B. H. (1996). Lithium use and discontinuation in a health maintenance organization. American Journal of Psychiatry, 153, 993-1000.
47. Kampman, M., Keijsers, G. P., Hoogduin, C. A., & Hendriks, G. J. (2002). A randomized, double-blind, placebo-controlled tudy of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. Journal of Clinical Psychiatry, 63, 772-777.
48. Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B. L., Duner, D. L., Gelenberg, A. J., et al. (2000). A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine, 342, 1462-1470.
49. Lam, D. H., Bright, J., Jones, S., Hayward, P., Schuck, N., Chisholm, D., et al. (2000). Cognitive therapy for bipolar disorder - A pilot study of relapse prevention. Cognitive Therapy and Research, 24 503-520.
50. Lam, D. H., Watkins, E. R., Hayward, P., Bright, J., Wright, K., Kerr, N., et al. (2003). A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder. Archives of General Psychiatry, 60, 145-152.
51. Lydiard, R. B., Brawman-Mintzer, O., & Ballenger, J. C. (1996). Recent developments in the psychopharmacology of anxiety disorders. Journal of Consulting and Clinical Psychology, 64(4), 660-668.
52. Marks, I. M., Swinson, R. P., Basaglu, M., Kuch, K., Nasirvani, H., O'Sullivan, G., et al. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled study in London and Toronto. British Journal of Psychiatry, 162, 776-787.
53. Mavissikalian, M., & Perel, J. M. (1993). Clinical experience in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Archives General Psychiatry, 49, 318-323.
54. Miklowitz, D. J., George, E. L., Richards, J. A., Simoneau, T. L., & Suddath, R. L. (2003). A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Archives of General Psychiatry, 60, 904-912.
55. Miklowitz, D. R., & Goldstein, M. J. (1997). Bipolar disorder: A family-focused treatment approach. New York: Guilford Press.
56. Miklowitz, D. J., Richards, J. A., George, E. L., Frank, E., Suddath, R. L., Powell, K. B., et al. (2003). Integrated family and individual therapy for bipolar disorder: Results of a treatment development study. Journal of Clinical Psychiatry, 64, 182-191.
57. Miklowitz, D. J., Simoneau, T. L., George, E. L., Richards, J. A., Kalbag, A., Sachs-Ericsson, N., et al. (2000). Family-focused treatment of bipolar disorder: One-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biological Psychiatry, 48 582 592.
58. Murphy, G., Simons, A., Wetzel, R., & Lustman, P. (1984). Cognitive therapy and pharmacotherapy, singly and together in the treatment of depression. Archives of General Psychiatry, 41, 33-41.
59. Newman, C. F., Leahy, R. L., Beck, A. T., Reilly-Harrington, N., & Gyulai, L. (2002). Bipolar disorder: A cognitive therapy approach. Washington, DC: American Psychological Association.
60. Noyes, R., Garvey, M. J., Cook, B. L., & Samuelson, L. (1989). Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. Journal of Clinical Psychiatry, 50, 163-169.
61. Noyes, R., Garvey, M. J., Cook, B., & Suelzer, M. (1991). Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. American Journal of Psychiatry, 148, 517-523.
62. O'Connell, R. A., Mayo, J. A., Flatlow, L., Cuthbertson, B., & O'Brien, B. E. (1991). Outcome of bipolar disorder on long-term treatment with lithium. British Journal of Psychiatry, 159, 123-129.
63. Otto, M. W. (2002). Learning and "unlearning" fears: Preparedness, neural pathways, and patients. Biological Psychiatry, 52 917-920.
64. Otto, M. W., Hinton, D., Korbly, N. B., Chea, A., Phalnarith, B., Gershuny, B. S., et al. (2003). Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: A pilot study of combination treatment with cognitive-behavior therapy vs. sertraline alone. Behaviour Research and Therapy, 41, 1271-1276.
65. Otto, M. W., Penava, S. J., Pollock, R. A., & Smoller, J. W. (1996). Cognitive-behavioral and pharmacologic perspectives on the treatment of post-traumatic stress disorder. In M. H. Pollack, M. W. Otto, & J. F. Rosenbaum (Eds.), Challenges in clinical practice: Pharmacologic and psychosocial strategies (pp. 219-260). New York: Guilford Press.
66. Otto, M. W., Pollack, M. H., & Maki, K. M. (2000). Empirically-supported treatment for panic disorder: Costs, benefits, and stepped care. Journal of Consulting and Clinical Psychology, 68, 556-563.
67. Otto, M. W., Pollack, M. H., Penava, S. J., & Zucker, B. G. (1999). Cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: A clinical case series. Behaviour Research and Therapy, 37, 763-770.
68. Otto, M. W., Pollack, M. H., & Sabatino, S. A. (1996). Maintenance of remission following cognitive-behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment. Behavior Therapy, 27, 473 482.
69. Otto, M. W., Pollack, M. H., Sachs, G. S., Reiter, S. R., Meltzer-Brody, S., & Rosenbaum, J. F. (1993). Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavior therapy for patients with panic disorder. American Journal of Psychiatry, 150, 1485-1490.
70. Otto, M. W., Reilly-Harrington, N., & Sachs, G. (2003). Psychoeducational and cognitive-behavioral strategies in the management of bipolar disorder. Journal of Affective Disorders, 73, 171-181.
71. Otto, M. W., Safren, S. A., Nicolaou, D. C., & Pollack, M. H. (2003). Considering mechanisms of action in the treatment of social anxiety disorder. In M. H. Pollack, N. M. Simon, & M. W. Otto (Eds.), Social phobia: Presentation, course, and treatment. New York: Castle Connolly Graduate Medical Publishing.
72. Perry, A., Tarrier, N., Morriss, R., McCarthy, E., & Limb, K. (1999). Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early warning signs or relapse and obtain treatment. British Medical Journal, 318, 149-153.
73. Pollack, M. H., Otto, M. W., Kaspi, S. P., Hammerness, P. G., & Rosenbaum, J. F. (1994). Cognitive-behavior therapy for treatment-refractory panic disorder. Journal of Clinical Psychiatry, 55, 200-205.
74. Pollack, M. H., & Smoller, J. W. (1996). Pharmacologic approaches to treatment resistant panic disorder. In M. H. Pollack & M. W. Otto (Eds.), Challenges in clinical practice: Pharmacological and psychosocial strategies (pp. 89-112). New York: Guilford.
75. Power, K. G., Simpson, R. J., Swanson, V., & Wallace, L. A. (1990). Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. British Journal of General Practice, 40(336), 289-294.
76. Rea, M. M., Tompson, M. C., Miklowitz, D. J., Goldtein, M. J., Hwang, S., & Mintz, J. (2003). Family-focused treatment versus individual treatment for bipolar disorder: Results of a randomized clinical trial. Journal of Consulting and Clinical Psychology, 71, 482-492.
77. Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., et al. (2004). Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobics to facilitate extinction of fear. Archives of General Psychiatry, 61, 1136-1147.
78. Schmidt, N. B., Wollaway-Bickel, K., Trakowski, J. H., Santiago, H. T., & Vasey, M. (2002). Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behaviour Research and Therapy, 40, 67-73.
79. Schwartz, B. L., Hashtroudi, S., Herting, R. L., Schwartz, P., & Deutsch. S. I. (1996). D-cycloserine enhances implicit memory in Alzheimer patients. Neurology 46(2), 420-424.
80. Scott, J., Garland, A., & Moorhead, S. (2001). A pilot study of cognitive therapy in bipolar disorders. Psychological Medicine, 31 459-467.
81. Simons, A. D., Murphy, G. E., Levine, J. L., & Wetzel, R. D. (1986). Cognitive therapy and pharmacotherapy for depression: Sustained improvement over one year. Archives of General Psychiatry, 43, 43-48.
82. Sirey, J. A., Meyers, B. S., Bruce, M. L., Alexopoulos, G. S., Perlick, D. A., & Raue, P. (1999). Predictors of antidepressant prescription and early use among depressed outpatients. American Journal of Psychiatry, 156(5), 690-696.
83. Spiegel, D. A., Bruce, T. J., Gregg, S. F., & Nuzzarello, A. (1994). Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder. American Journal of Psychiatry, 151 876-881.
84. Stewart, J. W., Mercier, M. A., Agosti, V., Guardin, M., & Quitkin, F. M. (1993). Imipramine is effective after unsuccessful cognitive therapy: Sequential use of cognitive therapy and imipramine in depressed outpatients. Journal of Clinical Psychopharmacology, 13, 114 119.
85. Sutherland, S. M., & Davidson, J. R. T. (1995). B-blockers and benzodiazepines in pharmacotherapy. In M. B. Stein (Ed.), Social phobia: Clinical and research perspectives (pp. 323-326). Washington, DC: American Psychiatric Press.
86. Telch, M. J., Agras, W. S., Taylor, C. B., Roth, W. T., & Gallen, C. (1985). Combined pharmacological and behavioral treatment for agoraphobia. Behaviour Research and Therapy, 23, 325-335.
87. Telch, M. J., & Lucas, R. A. (1994). Combined pharmacological and psychological treatment of panic disorder: Current status and future directions. In B. E. Wolfe & J. D. Maser (Eds.), Treatment of panic disorder (pp. 177-197). Washington, DC: American Psychiatric Association Press.
88. Tsai, G. E., Falk, W. E., Gunther, J., & Coyle, J. T. (1999). Improved cognition in alzheimer's disease with short-term d-cycloserine treatment. American Journal of Psychiatry, 156(3), 467-469.
89. van Balkom, A. J., de Haan, E., van Oppen, P., Spinhoven, P., Hoogduin, K. A., & van Dyck, R. (1998). Cognitive and behavioral therapies alone and in combination with fluvoxamine in the treatment of obsessive compulsive disorder. Journal of Nervous and Mental Disease, 186, 492-499.
90. Walker, D. L., Ressler, K. J., Lu, K. T., & Davis, M. (2002). Facilitation of conditioned fear extinction by systemic administration of intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. Journal of Neuroscience, 22, 2343 2351.
91. Weilburg, J. B., O'Leary, K. M., Meigs, J. B., Hennen, J., & Stafford, R. S. (2003). Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatric Services, 54(9), 1233-1239.
92. Whittal, M. L., Otto, M. W., & Hong, J. J. (2001). Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: A case series. Behaviour Research and Therapy, 39, 939 945.
93. Zaretsky, A. E., Segal, Z, V., & Gemar, M. (1999). Cognitive therapy for bipolar depression: A pilot study. Canadian Journal of Psychiatry, 44, 491-494.